Many new options for prostate cancer

PROSTATE CANCER:

Until recently, there were very few options for the treatment of advanced prostate cancer.  Now, there are many new agents available including:

1.  Firmagon (degarelix) - It decreases the level of testosterone (the 
    hormone which fuels prostate cancer).


2.  Zytiga (abiraterone) - inhibits the enzyme CYP17, which ultimately 
    causes less testosterone production.


3.  Jevtana (cabazitaxel) - a chemotherapy agent used in combination
     with prednisone for patients who have had progression of disease
     after using anti-testosterone treatment and Taxotere (docetaxel), a
     related chemotherapy drug. 

4.  Xtandi (enzalutimide) -oral drug which inhibits the receptor for 
     testosterone on prostate cancer cells for patients with metastatic
     disease (spread outside the prostate) that have failed treatment with 
     other anti-testosterone treatments and Taxotere. 

5.  Provenge (sipuleucel-T) - a vaccine made from each prostate cancer 
     patient's specific cancer tissue and then injected into the patient.  

Ask your oncologist for further details.